摘要:
A compound of formula (1) is useful as a pharmaceutical and as an intermediate in making paliperidone, wherein Y is an acid-sensitive group of the formula (A') in which X represents an oxygen atom, a sulfur atom, or an -NH- group; Z represents a C2-C7 alkylene bridge; and R represents hydrogen or a C1-C4 alkyl group.
摘要:
A process for making montelukast, a pharmaceutically useful compound of the following formula and salts thereof: formula (1), using a compound of formula (20) and a compound of formula (5) is provided.
摘要:
The invention relates to a process for making the compound of general formula (I), or an acid addition salt wherein the dotted line indicates a carbon-carbon bond on the asymmetric carbon, which process comprises the steps of a) the reaction of the compound of formula (II), wherein the dotted line has the same meaning, with bis(p-nitrophenyl)carbonate of the formula (IX) preferably at the temperature between -20 to 50°C and in an inert solvent, followed by b) the reaction of the so formed intermediate of the formula (VII-1) with ethylmethylamine of the formula (III), preferably at the temperature between -20 to 50°C and in an inert solvent, and to novel compounds and their use in the synthesis of rivastigmine.
摘要:
Racemic tamsulosin free base is obtained in solid form. The solid form can be formed by precipitating racemic tamsulosin free base from a solvent that comprises at least one of water or a lower alcohol. The crystalline free base exhibits polymorphism and two unique forms are identified. Novel intermediates are disclosed useful in the production of tamsulosin free base: a sulfonic acid salt of 2-(o-ethoxyphenoxy)ethylamine and (3-aminosulfonyl-4-methoxy)phenylacetone.
摘要:
Desvenlafaxine is formed from venlafaxine by the use of a demethylating agent comprising a metal sulfide, such as sodium sulfide, and optionally selenium.
摘要:
A process for making montelukast, a pharmaceutically useful compound of the following formula and salts thereof: formula (1), using a compound of formula (20) and a compound of formula (5) is provided.
摘要:
Optically impure tamsulosin including racemic tamsulosin can be resolved into optically pure (R)- or (S)-tamsulosin by the use of diastereomeric sulfonate salts of tamsulosin in a fractional crystallization technique.
摘要:
The invention relates to a compound or composition comprising N-formyl paroxetine of formula (1) and 0 to 99.97% of a paroxetine compound, based on the combined weight of said N-formyl paroxetine and said paroxetine compound, to a pharmaceutical composition, for treating a selective serotonin reuptake inhibitor-treatable disease or condition, comprising an effective amount of a paroxetine agent and at least one pharmaceutically acceptable excipient, wherein said paroxetine agent comprises of an N-formyl paroxetine compound of formula (1) and optionally a paroxetine compound, and to a process for producing a paroxetine compound which comprises treating an N-formyl paroxetine compound of formula (1) with a de-formylation agent, to a compound having the formula (2), to a process for determining the stability or purity of a paroxetine substance or composition, which comprises assaying a paroxetine substance or composition for the presence of an N-formyl paroxetine compound of formula (1), and to a process assaying the quality of paroxetine, which comprises forming a production lot of paroxetine pharmaceutical solid dosage forms wherein each dosage form comprises paroxetine or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable exipient; removing a sample of said paroxetine pharmaceutical solid dosage forms from said production lot; assaying said sample for the presence and/or amount of N-formyl paroxetine; and selling or releasing said production lot if said sample passes said assay with respect to the presence or amount of N-formyl paroxetine.